Immune phenotypes predict survival in patients with glioblastoma multiforme by Mostafa, Haouraa et al.
RESEARCH Open Access
Immune phenotypes predict survival in
patients with glioblastoma multiforme
Haouraa Mostafa1,2, Andrej Pala3, Josef Högel4, Michal Hlavac3, Elvira Dietrich1,2, M. Andrew Westhoff5,
Lisa Nonnenmacher3, Timo Burster3, Michael Georgieff2, C. Rainer Wirtz3 and E. Marion Schneider1,2*
Abstract
Background: Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond
the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological
control in individual patients with GBM.
Methods: Immune phenotypes and plasma biomarkers of GBM patients were determined at the time of diagnosis
using flow cytometry and ELISA, respectively.
Results: Using descriptive statistics, we found that immune anomalies were distinct in individual patients. Defined
marker profiles proved highly relevant for survival. A remarkable relation between activated NK cells and improved
survival in GBM patients was in contrast to increased CD39 and IL-10 in patients with a detrimental course and very
short survival. Recursive partitioning analysis (RPA) and Cox proportional hazards models substantiated the
relevance of absolute numbers of CD8 cells and low numbers of CD39 cells for better survival.
Conclusions: Defined alterations of the immune system may guide the course of disease in patients with GBM
and may be prognostically valuable for longitudinal studies or can be applied for immune intervention.
Keywords: Glioblastoma multiforme, CD8+ lymphocytes, NK cells, CD39-ectonucleotidase, Recursive partitioning
analysis, Survival
Background
Glioblastoma multiforme (GBM) is the most common pri-
mary brain tumor in adults. Despite intensive research
efforts and a multimodal management that consists of sur-
gery, radiotherapy, and chemotherapy with temozolomide,
the prognosis is very poor [1]. The hypoxic environment
represents a very potent stimulus for angiogenesis [2],
while molecular alterations, cell survival mechanisms, the
acquisition of chemo- and radioresistance [3], and tumor
heterogeneity [4] as well as multiple immune escape
mechanisms are further important factors that contribute
to the inferior prognosis in GBM [5, 6]. In addition to age,
a number of stress factors, including chemical exposure,
and demographical aspects influence the incidence of
tumor manifestation [7]. At least one study demonstrated
an increased risk for glioblastoma by alcohol consumption
[8]. When compared with other malignancies, modulation
of immune suppressor effector cells appears to be of
major importance [9], and individual tumor patients may
require an individual treatment regimen against im-
mune suppressive elements. We addressed here im-
mune phenotypes in patients with glioblastoma at the
time of diagnosis. We applied flow cytometry and vali-
dated enzyme-linked immunosorbent assay (ELISA) as
a reliable technique to systematically analyze immune
cells in peripheral blood as well as cytokines. In gen-
eral, immune modulation initiated by the tumor may
require direct cell-cell contact or may occur via soluble
factors, including interleukins and chemokines. At
present, malignancies manifesting distantly from the
peripheral immune system have not been systematically
described to influence immune phenotypes. However,
an important work published by Kmiecik and colleagues
[10], which was performed in a small group of GBM pa-
tients, was highly promising in implying the sensitization
* Correspondence: marion.schneider@uni-ulm.de
1Sektion Experimentelle Anaesthesiologie, University Hospital Ulm, Albert
Einstein Allee 23, 89081 Ulm, Germany
2Klinik für Anaesthesiologie, University Hospital Ulm, Albert Einstein Allee 23,
89081 Ulm, Germany
Full list of author information is available at the end of the article
© 2016 Mostafa et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mostafa et al. Journal of Hematology & Oncology  (2016) 9:77 
DOI 10.1186/s13045-016-0272-3
of immune cells against GBM. In addition, the work
published by Skog and coworkers [11] contributed to our
understanding of effector pathways induced by the inter-
action of tumor-derived microparticles with target cells.
Cytokines, including interleukin (IL)-10 and ferritin, se-
creted by tumor-infiltrating immune cells and by the
tumor itself are members of a larger scenario of a tumor-
associated proteome [12]. They may play an important
role in downregulating major histocompatibility complex
(MHC)-class I and natural killer (NK)-ligands [13].
Here, we asked whether immune phenotypes of pa-
tients with manifest GBM display distinct features dif-
fering from healthy individuals. In addition to the
abovementioned IL-10 and ferritin associated with
GBM, we found that the relative amounts of activated
NK cells in addition to T cell receptor (TCR) α/β-posi-
tive and CD8-positive lymphocytes display a strong cor-
relation with increased survival in GBM in bivariate
analysis. When using multivariable Cox proportional
hazards model analysis, the Karnofsky Performance sta-
tus Scale (KPS), the isocitrate dehydrogenase-1 (IDH-1)
mutation status, and high CD8 and low CD39 cells are
most relevant for better survival.
Methods
Patients
Patients had been diagnosed for glioblastoma multi-
forme grade IV according to the criteria of the World
Health Organization (WHO). Immune competence was
tested at the time of diagnosis before surgery following
standard cluster of differentiation (CD) and activation
markers for T-, NK-, monocyte-, and granulocyte sub-
populations according to international guidelines for
whole blood flow cytometric analysis. Immune pheno-
typing and inflammatory and anti-inflammatory bio-
markers performed by a validated ELISA was an
essential step in classifying patients for their immune
competence. These tests were done for each patient as
part of routine care. Patients were then under high dose
steroid treatment. All patients’ data were pseudonymized
by a data bank held in the Section of Experimental An-
aesthesiology (http://www.uniklinik-ulm.de/struktur/kli-
niken/sektionen/klinik-fuer-anaesthesiologie/experimen-
telleanaesthesiologie/home/general-information/address-
contact.html). The study was conducted after approval
by the local Ethics Committee of the University Hospital
Ulm with the approval umber 162/10 named “Novel ex-
perimental approaches in brain tumors”. The universal
trial number is U111-1179-3127. Brain tumor material
was used to establish cell lines. Two milliliters of
ethylenediaminetetra-acetic acid (EDTA) anti-coagulated
blood were routinely analyzed from all patients at the
time of diagnosis before surgery. A total of 51 patients
were assessed. The mean age was 56.8 years (range
22–78 years). All patients underwent surgical resection,
radiotherapy, and chemotherapy and had routine follow-
up with magnetic resonance imaging interpreted by neu-
roradiologists. All patients are listed in Table 1.
Healthy donors
A total of 36 healthy volunteers were included as controls.
Their mean age was 36.1 years (range 19–68 years). Their
immune phenotypes and plasma biomarkers were also
based on routine analysis in the context of routine clinical
examination. Results of all healthy donors were also
pseudonymized before processing for statistical analysis.
Flow cytometry
Surface markers of whole blood leukocytes were deter-
mined by standard flow cytometric analyses using FACS-
calibur and Cellquest software (BD Biosciences.com).
Leukocytes were gated into lymphocytes, monocytes,
and granulocytes by forward- and side-scatter analysis.
Quantification of the percent-positive cells was deter-
mined by the binding of fluorescently labeled antibodies
and determination of expression densities of individual
antigens was recorded. The expression density of the
relevant antigens was calculated as the mean fluores-
cence intensity (MFI) using the following formula: (%
positives ×mean expression density of the relevant anti-
gen) − (% positives × mean expression density of the re-
spective isotype control). The following antibodies were
determined on lymphocytes: IgG1 and IgG2a isotype con-
trol antibodies, monoclonal antibodies directed against
CD3ε-chain (clone UCHT1, Beckmancoulter.com), TCRα/
β (clone WT31), CD56 (clone My31), CD4 (clone SK3),
CD25 (clone M-A251), CD8 (clone 2ST8.5H7, Beckman-
Coulter.com), CD16 (NK-P15), CD95 (clone DX-2),
CD127 (clone #40131, RnD Systems), and CD39 (clone
A1, abdserotec.com), all purchased from BD Biosciences.-
com, if not stated otherwise. Since all patients were ana-
lyzed during high steroid treatment, we also addressed the
phenotype of two GBM patients before and after steroid
medication (Additional file 1: Figure S1).
Plasma biomarkers
Plasma from patients’ blood and control subjects was used
for the quantification of biomarkers. A highly sensitive
and validated ELISA (Immulite 1000®, Siemens.com) was
used. The following Immulite 1000® kits were used: I10 to
quantify IL-10 and FER to quantify plasma ferritin.
MGMT analysis and IDH-1 mutation status
To analyze MGMT-promoter methylation, DNA was ex-
tracted from snap-frozen tumor tissue. A pyrosequenc-
ing platform (ID or Q24 instrument, Qiagen.com) was
applied for the quantification of methylation status at a
single base solution. Quantitative methylation values
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Table 1 Patients’ list showing age and sex, tumor location, total or subtotal resection, O6-methylguanine-DNA methyltransferase
(MGMT), IDH-1 mutation status, and overall survival
Patient no. Age/sex Tumor location Resection MGMT IDH mutation Overall survival (months)
#1 60/m Ttemporo-occipital Subtotal p n.a. 31
#2 62/m Temporal Total n n 9
#3 41/f Fronto-parietal Total n n 18+
#4 65/m Frontal Total p n 10
#5 34/m Frontal Subtotal p n 19+
#6 34/f Occipital Total n n.a. n.a.
#7 44/f Frontal Subtotal n n 11
#8 54/m Temporal Total n n 23
#9 66/m Parietal Subtotal n n 25
#10 29/m Temporal Total p p 43+
#11 68/m Parieto-occipital Total n n 14
#12 71/m Temporo-occipital Subtotal n n 16+
#13 78/f Frontal Biopsy p n 15
#14 70/m Temporal Subtotal n n 10+
#15 45/m Parieto-occipital Subtotal p p 12+
#16 61/m Temporo-occipital Subtotal n n 11+
#17 52/m Temporal Total n n 10+
#18 63/f Frontal Total n n 7
#19 61/f Frontal Total p n.a. 53+
#20 41/m Fronto-parietal Subtotal n n 33
#21 75/m Frontal Subtotal n n 3
#22 74/f Temporal Subtotal p p 52
#23 57/m Temporal Subtotal n n 23
#24 22/m Frontal Subtotal p n 77
#25 56/m Fronto-parietal Subtotal n p 7
#26 44/m Parietal Subtotal p p 18+
#27 51/m Frontal Total p n 10
#28 67/f Frontal Total n.a. p 28+
#29 53/f Frontal Total n n 20+
#30 45/m Temporo-parietal Subtotal p p 31
#31 58/m Frontal Total n n 9+
#32 58/m Frontal Total n p 7+
#33 53/f Temporo-occipital Subtotal p n 5
#34 67/f Frontal Total p n 8+
#35 62/m Frontal + temporal Total n n 8+
#36 67/m Temporal Total n n 9+
#37 74/m Occipital Subtotal n n 9+
#38 54/m Temporal Subtotal n.a. n 7
#39 70/m Frontal Total p n 5+
#40 40/m Temporo-occipital Subtotal p n 61+
#41 68/f Temporo-occipital Total p n 6
#42 38/m Parietal Total p n 5+
#43 76/f Temporal Near total p p 25+
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within a sequence context were determined for individ-
ual or multiple CpG sites. (http://www.varionostic.de/
services/dna-methylation/)
IDH-1 mutation status was tested by a monoclonal
antibody directed against the most frequent mutation
site: IDH1 R132H [14].
Statistics
Descriptive statistics, including medians, interquartile
ranges, and 10th and 90th percentiles were applied to
characterize leukocyte blood parameters and surface an-
tigens in healthy donors vs. controls. Between-group
comparisons of continuous variables were performed
using the Mann-Whitney U test. The Kaplan-Meier
method and log-rank test were applied to summarize
and compare the overall survival and time to progres-
sion between trials or different conditions using Graph-
PadPrism version 6.0 or the SAS procedure “LIFETEST”.
In this context, median values were used as cutoffs to
dichotomize continuous traits for survival analysis. For
the purpose of prediction, Cox proportional hazards
models were fitted using SAS PROC PHREG. Only
parameters which showed a p value < 0.2 in univari-
able analysis (Additional file 2: Table S1) were in-
cluded in the multivariable Cox proportional hazards
model (Additional file 3: Table S2). Unbiased recur-
sive partitioning analysis (RPA) was applied to identify
the risk classes. Absolute numbers of leukocytes and
leukocyte subpopulations were determined by routine
Coulter counting determinations. For all statistical
investigations, tests for significance were two-tailed,
with a p value threshold of 0.05 indicating “statistical
significance”.
Results
IL-10 and plasma ferritin are elevated in GBM
We determined two biomarkers in the patients’ plasma
before surgery: IL-10 and plasma ferritin. The median
values of IL-10 and ferritin were significantly elevated in
the GBM patients (Fig. 1). Patients with IDH-1 muta-
tions are labeled in red.
CD3 expression densities are reduced in GBM
In standard flow cytometry to test differentiation anti-
gens (defined by CD clusters) in peripheral blood cells of
patients with GBM, several markers displayed different
profiles compared to healthy donors. In particular, we
found a reduced relative amount of CD3-positive lym-
phocytes in the lymphocyte gate of GBM patients (p <
0.0001). In addition, the mean expression density of
CD3 as determined by the MFI value was also signifi-
cantly decreased (p = 0.0046) when compared with pro-
files obtained from healthy donors (Fig. 2a). Ranges of
reference numbers of absolute CD3-positive cells are in-
dicated as blue arrowheads. Furthermore, the relative
amount for the TCRα/β determined by the WT31 clone
was also significantly diminished (p < 0.0001; Fig. 2b).
Most remarkable was the large variation in CD3- and
TCRα/β-positive lymphocytes in the GBM patients when
compared with the healthy controls. However, when
plotting the MFI values, both the GBM patients and
healthy controls displayed a larger expression range
(CD3 MFI: GBM: 261–41,500; controls: 4,800–36,700
and TCRα/β: GBM: 2,400–21,000; controls: 2,100–
23,000), which indicates that a difference between GBM
and the controls for immune competence (CD3, TCRα/
β) is likely to be due to receptor expression densities
and the presence of other lymphocyte subpopulations
in GBM which are not observed in healthy donors. To
determine whether these alterations were potentially re-
lated to lymphocyte activation states, the amount and
expression densities of CD95 were also plotted. The
lymphocytes of GBM patients expressed slightly more
CD95 than those of healthy donors (Fig. 2c). One GBM
patient had a very high CD95 MFI (#22); however, ab-
solute numbers of CD95-positive lymphocytes are
highly elevated in five patients, two of which are IDH-1
mutated. These two patients (#32, #15) also had ele-
vated CD3 and TCRα/β-positive lymphocyte counts.
Table 1 Patients’ list showing age and sex, tumor location, total or subtotal resection, O6-methylguanine-DNA methyltransferase
(MGMT), IDH-1 mutation status, and overall survival (Continued)
#44 72/f Parietal Subtotal n p n.a.
#45 53/f Temporal Total n n 8+
#46 39/m Frontal Total p p 120+
#47 77/f Pareital Total p n 7+
#48 75/f Temporo-parietal Subtotal p p 4+
#49 24/f Parietal Total n p 85+
#50 64/m Temporo-parietal Subtotal p n 4+
#51 65/f Fronto-parietal Near total n n 4+
All patients labeled with “+” remained to be alive until to date
n negative, p positive, m male, f female, n.a. not available
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NK cell subpopulations in GBM and healthy donors
Similar data sets are displayed in Fig. 2; the relative and
absolute amounts of CD56+ NK-cells are presented in
Fig. 3. Although the percentage of CD56+ NK cells var-
ied with a large range in GBM, the median values were
not significantly different from healthy donors (p =
0.6857; Fig. 3a). However, when the MFI values were cal-
culated, there was a trend for lower CD56 expression in
GBM when compared with the lymphocyte fraction of
healthy donors (p = 0.0972; Fig. 3a). Absolute numbers
of CD56+ NK-cells again demonstrate that some patients
are unique and differ from values determined in healthy
donors of advanced age [15]. Generally, these results
suggest that GBM patients may have more CD56dim NK
cells than cytokine-producing CD56bright cells. We fur-
ther investigated CD56+ NK cells co-expressing the acti-
vation antigen CD16. The majority of GBM samples did
not differ from the control (Fig. 3b). However, there
were unique individual GBM patients with very high
relative amounts of CD16-positive NK cells, indicating
NK-cell activation. When plotting MFI values, individ-
uals with a high CD16 expression in CD56-positive NK
cells could also be identified (Fig. 3b). Nevertheless, of
particular interest were patients #12, #21, #23, and #26,
who displayed elevated or very elevated CD16/CD56-
positive NK cells before surgery; however, only #6 had
high amounts of absolute CD16/CD56-positive lympho-
cytes, all within the normal range of healthy individuals
at an advanced age [15]. NK cells co-expressing CD3, a
T-cell receptor structure, in addition to NK markers de-
fine a cell type which is particularly sensitive to cytokine
activation and have been termed cytokine-induced killer
(CIK) cells; they exhibit non-MHC-restricted cytolysis
activities against tumor cells [16]. Such CD3/56 co-
expressing effectors were clearly diminished in the
majority of GBM patients (Fig. 3c, p = 0.0016), but two
patients (#14 and #25) were characterized by a very high
proportion of this cell type. An attenuated phenotype
was also detected in a few healthy donors. The absolute
numbers of CIK were higher in healthy donors [15].
Evidence for regulatory T cell subsets in GBM patients
and healthy controls
GBM patients had a very low relative amount of CD4-
positive cells (#22, #23, #26, #40) (Fig. 4a), in part corre-
sponding to low absolute numbers. IDH-1-mutated
tumor patients display either increased or decreased
CD4-positive lymphocytes (Fig. 4b). One IDH-1-mutated
patient (#32) had very high CD3-, TCRα/β-, and CD95-
positive lymphocytes (Fig. 2). CD8-positive lymphocytes
are also heterogeneous between GBM patients and con-
trols (Fig. 4b). This accounts for the percentage of CD8-
positive lymphocytes and their expression densities
(MFI), as well as the absolute numbers (Fig. 4b). Two
patients with high absolute numbers of CD8-positive
cells (#24, #28) also presented with high amounts of
CD16/CD56-positive cells (Fig. 3b), but not with increased
CD3- and TCRα/β-positive lymphocytes (Fig. 2b). The
distribution of lymphocytes co-expressing CD4 and
CD25 characterizes an activated lymphocyte subpopula-
tion, which contains a large proportion of so-called
regulatory, that is, immune suppressive T lymphocytes.
The further characterization of CD4/CD25 lymphocytes
led to the recognition of the importance of FoxP3
expression, a transcription factor involved in the sup-
pressive function of this cell type. FoxP3 was not deter-
mined in our study, but according to a recent review,
active FoxP3 is mostly restricted to the CD4/CD25 high
T cell subpopulation in humans [17]. According to per-
ipheral blood lymphocyte analyses, neither the median
percentage nor the MFI of CD4/CD25-positive lympho-
cytes in GBM patients and control individuals was sig-
nificantly different (Fig. 4c). In addition, an important
immune suppressive function is displayed by the ex-
pression of ATP-degrading enzymes, including CD39;
in lymphocytes with low IL-7 receptor, CD127 median
values are different between patients and healthy
donors (Fig. 4e). Among patients with high absolute
numbers of CD39, one IDH-1-mutated patient (#48)
presented with very high relative and absolute numbers
in addition to high CD39 expression densities (Fig. 4d).
Fig. 1 Increased median value of IL-10 and ferritin in plasma samples of GBM patients. Interleukin 10 (IL-10) (a), plasma ferritin (b) as relevant
biomarkers determined in plasma samples of GBM patients (P) and healthy controls (H). Median values for IL-10 is 7.18 (±1.2 pg/ml) in elderly
healthy donors, and ferritin serum concentrations may range a lot in elderly. IDH-1 mutated patients outside of the 25–75 boxed percentile are
shown as red-filled circles
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Results suggest that CD39 may play a unique role in
immune suppression of GBM. Exemplary analysis of
GBM tissue preparations suggests that CD39 is also
expressed in tumor tissue (Additional file 4: Figure S2).
Regulatory T cells (Tregs) are also defined by weak ex-
pression of the IL-7 receptor, CD127 (p = 0.0083).
Figure 4e shows the differences of medians of CD127-
positive lymphocytes in GBM and controls as compared
with the respective expression densities of CD127.
Patients with GBM displayed a lower median of CD127-
positive lymphocytes as well as a MFI of CD127. Remark-
ably, the absolute numbers of CD127-positive cells were
also increased in patient #48, who was unique by high
CD39 (Fig. 4e).
Immune phenotypes correlate with survival in GBM
Figure 5 shows the overall survival of the GBM pa-
tients and the different survival curves in association
Fig. 2 Significantly decreased CD3 and TCR α/β in peripheral blood cells but no significant change in CD95. Percent CD3 lymphocytes in EDTA
whole-blood-derived lymphocytes of GBM patients (P) and controls (H) (a, left) and the corresponding CD3 expression densities (mean
fluorescence intensity (MFI)) (a, middle) and absolute numbers of CD3-positive lymphocytes in patients (a, right). Normal ranges of absolute
numbers are indicated as blue arrowheads on the y-axis (a, right). Percent TCRα/β lymphocytes in GBM patients and healthy controls (b, left) and the
corresponding MFI distribution (b, middle) and absolute numbers of TCRα/β cells/μl blood (b, right). Percent CD95 lymphocytes in GBM patients as
compared to controls (c, left) and the corresponding distribution of CD95 MFI (c, middle) and absolute CD95-expressing lymphocytes (c, right).
IDH-1 mutated patients outside of the 25–75 boxed percentile are shown as red-filled circles. IDH-1 mutated patients outside of the 25–75
boxed percentile are shown as red-filled circles
Mostafa et al. Journal of Hematology & Oncology  (2016) 9:77 Page 6 of 14
with immune markers differentially expressed in pa-
tients and controls. The median overall survival was
19 months (Fig. 5a). We then analyzed the survival in
the context of immune markers. Patients were grouped
according to their marker distribution higher or lower
of the respective median value. Patients with more than
30 % CD8 expressing differed from those with < 30 %
CD8-positive cells, by a better median survival (19 vs.
10 months (p = 0.0419), Fig. 5b). TCRα/β expression of
>51.2 % as compared to < 51.2 % TCRα/β T cells re-
sulted in significantly better survival of 43 vs. 9 months
(p = 0.0498; Fig. 5c). CD95 differences were in the same
range: With a cutoff of 60.5 %, the median survival was
8 and 43 months, respectively (p = 0.047, Fig. 5d). The
activation marker CD16 on CD56+ NK cells of (> 8.35
vs. <8.35 %) resulted in a median survival of 53 vs.
10 months (p = 0.0031, Fig. 5e). CD127-expressing
lymphocytes were analyzed in two groups with > 18.5
Fig. 3 Differences in CD56 and CD16/56 NK cells and CD3/56 cytokine-activated NK (CIK) cells in GBM patients and controls. Percent CD
cluster-positive lymphocytes are shown for patients (P) and healthy donors (H) on the left; relative expression densities, given as MFI are shown
in the middle column, and absolute numbers of CD cluster-positive lymphocytes for the patients are shown on the right half of the figure.
CD56 NK cells (a). CD56/16 co-expressing, activated NK cells (b). CD3/56 co-expressing, cytokine-induced killer (CIK) cells (c). IDH-1mutated
patients outside of the 25-75 boxed percentile are shown as red-filled circles
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vs. < 18.5 % positive cells. The median survival in the
low and high CD127 groups was 25 and 11 months, re-
spectively (p = 0.0857, Fig. 5f ). The IDH-1 mutation
showed no evidence for a different survival (p = 0.6656,
Fig. 5h). Despite strong arguments for lymphocyte sub-
populations in GBM patients and survival, high
Fig. 4 Differences in CD8, CD4, CD4/25, CD39, and CD127-positive lymphocytes. Percent CD cluster-positive lymphocytes are shown for patients
(P) and healthy donors (H) on the left; relative expression densities, given as MFI are shown in the middle column, and absolute numbers of CD
cluster positive lymphocytes for the patients are shown on the right half of the figure. CD8 (a). CD4 (b). CD4+/CD25+ (c). CD39 (d). CD127 (e).
IDH-1 mutated patients outside of the 25-75 boxed percentile are shown as red-filled circles
Mostafa et al. Journal of Hematology & Oncology  (2016) 9:77 Page 8 of 14
absolute leukocyte counts (c.f. Additional file 5: Figure
S3) are related to inferior survival when analyzed by
univariable Cox regression analysis and multivariable
Cox proportional hazards model (Additional file 2:
Table S1, Additional file 3: Table S2, Additional file 6:
Figure S4).
Discussion
In the attempt to answer the question whether the per-
ipheral immune system senses a brain tumor, we investi-
gated lymphocyte subpopulations in peripheral blood
shortly before surgery. These analyses are potentially
hampered by steroids administered to acutely ill patients
Fig. 5 Kaplan-Meier curves of overall survival and lymphocyte subpopulations, IDH-1 and MGMT mutation status. Overall survival of 51 patients
with GBM (a), distinguished by relative amounts of CD expressing lymphocytes. Patients were grouped according to the median values of markers
determined by Mann-Whitney U statistical analysis. CD8 cells (b), TCRα/β T cells (c), CD95 expressing lymphocytes (d), CD16/56 activated NK cells
(e), and CD127 expressing lymphocytes (f); IDH-1 mutation status (g) and MGMT mutation status (h)
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before admission. All of our patients had steroid treatment
before surgery. However, a major effect on lymphocyte
subpopulations was not observed in two patients which
were investigated before and 1–3 days after steroid treat-
ment. By contrast, monocyte numbers were significantly
affected (Additional file 1: Figure S1).
GBM patients show reduced amounts of CD3 and TCRα/β
GBM patients presented with reduced numbers and
expression densities of CD3 and the TCRα/β. CD3 is an
essential member of the TCR complex and different
chains of the CD3 complex contribute to signaling of
the TCR. T-cell activation results in up-regulation of the
CD3 complex. When the CD3-expression density is sig-
nificantly diminished in patients compared to healthy
donors, this indicates impaired responsiveness by TCR-
mediated activation. In addition, the expression of the
TCRα/β complex was also different between the GBM
patients and controls, a fact which may be related to im-
mune suppression by a higher proportion of immune
regulatory elements [6] including cytokines, such as IL-
10 [18, 19].
Elevated levels of IL-10 and ferritin in GBM patients
The immune suppressive and activation pathways in
GBM were addressed by quantification of two plasma
biomarkers: IL-10 and plasma ferritin. The IL-10 median
was higher in GBM (p = 0.0006). In addition to immune
suppression, a direct effect of IL-10 on GBM prolifera-
tion has been reported [20, 21]. Higher ferritin was also
detected in GBM patients (p < 0.0001) and may be re-
lated to tumor-associated changes in iron hemostasis
[22] as well as macrophage activation, which has also
been documented by investigating macrophage infiltra-
tion in GBM tissue [23].
Reduced amounts of CD56 NK cells in GBM patients
Due to low or even negative MHC expression in GBM,
the activation of NK cells may contribute to immune
surveillance. A difference in NK cell numbers was found
in a subpopulation of GBM patients by using the broad
NK marker CD56 (Fig. 2). The remaining GBM patients
were similar to healthy donors. NK cells may be either
cytotoxic (CD56dim) or secreting cytokines (CD56bright),
and co-expressing CD16, when activated [24]. A defined
group of our GBM patients (n = 16/51) presented with
greater numbers of CD56 NK cells (Fig. 3). Since the
majority of GBM are low in MHC expression, NK cells
have been favored to target GBM tumors by immune
therapeutic approaches [25]. Whether activated NK cells
detected in a subgroup of GBM patients (Fig. 3b) indeed
recognize GBM targets awaits further analysis. Cytokine
activation also triggers NK function in CD3-expressing
lymphocytes. As shown in Fig. 3c, 5/51 patients and 3/36
healthy donors had increased numbers of such CIK
[26]. This cell population can be generated from TCR
α/β-positive T cells, acquires NK-receptor expression
by cytokine activation, and displays important tumor-
specific cytolysis [26]. Absolute numbers of CIK are
also higher in four patients, two of which were IDH-1
positive, when compared with reference values of eld-
erly healthy donors [15].
Reduced amounts of CD4 and CD8 but increased CD39
CIK may also express CD4 and CD8. CD8-positive lym-
phocytes T cells were distinct in GBM patients both in
terms of their relative numbers and expression densities.
CD8 is expressed as a homodimer (α/α) in suppressive T
lymphocytes presenting with a high CD8 expression
density because monoclonal antibodies applied in flow
cytometry detect the alpha chain. In contrast, cytotoxic
T lymphocytes co-express the CD8β chain and appear
with a lower CD8 MFI [27]. Accordingly, GBM patients
had higher amounts of potentially cytotoxic, i.e., CD8α/β
co-expressing lymphocytes. Absolute numbers of CD8
cells were high in four GBM patients but remained in
the normal range of healthy, elderly donors (Fig. 4b).
Interestingly, higher absolute numbers of CD8-positive
lymphocytes was an important characteristic for better
survival, in addition to the IDH-1 mutation status and
high KPS according to RPA (Additional file 6: Figure S4).
These results are in line with promising results of
tumor vaccination attempts [28] and may eventually
support vaccination in IDH-1-mutated glioblastoma
[14]. We also investigated CD4-positive lymphocyte
subpopulations. Similar to a previous study performed
by RNA expression analysis [29], we found that GBM
patients had less relative amounts of CD4-positive
lymphocytes and a reduced expression density of CD4
(Fig. 4a). Absolute amounts of CD4-positive lympho-
cytes were also lower when compared with reference
values of healthy individuals > 50 years of age [30]. An
important subpopulation of CD4-positive T cells is the
CD4/25 co-expressing activated T cell. Parts of these
comprise activated T cells and Tregs. CD4/25-positive
Tregs have been previously shown to play a critical
role in glioma-related immune surveillance [31]. This
observation is supported in appropriate mouse models
with experimental brain tumors [32]. In our analysis,
the absolute numbers of a CD4/25 population clearly
increased in GBM (up to 410/μl, Fig. 4c) when compared
with the reference values of CD4/CD25 co-expressing
lymphocytes (7–60 cell/μl [30]). In contrast, GBM patients
presented with a higher relative amount of another marker
protein expressed in Tregs, CD39. CD39 is a membrane-
bound nucleotidase, which promotes survival in an ATP-
rich environment and counteracts ATP-induced apoptosis
[33]. Currently, CD39 positivity is regarded superior to
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FoxP3 expression in the characterization of Tregs [34, 35].
The median difference of CD39 positivity determined as
the percent and expression density (MFI) was significant
between the healthy donors and patients (p < 0.0001
and p = 0.0003, respectively). These observations are
in agreement with a previous study analyzing CD39-
positive lymphocytes cooperating with CD73 in GBM pa-
tients [36]. Preliminary investigation suggests that CD39 ex-
pression is positive in GBM tumor tissue (Additional file 4:
Figure S2), an observation that needs to be further ad-
dressed in the future. Tregs expressing CD39 are further
defined by a low CD127 expression density [37, 38]. Indeed,
the percent CD127-positive lymphocytes were decreased in
GBM patients; results were significant for CD127 fluores-
cence intensities (Fig. 4e), and some patients were unique
by high absolute amounts of CD127 cells (including the
IDH-patient #48 with inferior survival).
Overall survival of GBM patients
Kaplan-Meier analysis has been performed for several
markers including median of overall survival which
was 19 months (Fig. 5), which is similar to published
data in patients treated using standard surgery and
radio-chemotherapy [39]. In addition to a major influ-
ence of neurosurgical intervention [40], immune char-
acteristics of the peripheral immune system may
influence tumor recurrence and survival. Expression
of TCRα/β and CD8 was related to improved survival
(Fig. 5b, Additional file 6: Figure S4); these results cor-
respond to data generated by mRNA profiling [29]. In
general, we followed the design of a previous study in
which immune markers of blood leukocytes were
found to be predictive for survival [10]. Such studies
will improve our knowledge about the detrimental co-
operative effects between the brain tumor and the per-
ipheral immune system even better when performed
as follow-up studies after tumor resection. As a hy-
pothesis provided in Fig. 6, tumor cells appear to in-
duce CD39 expressing regulatory T cells by direct or
tumor microenvironment-related interactions. Second,
neoantigens expressed by tumor tissues such as mu-
tated IDH-1 may be responsible for the activation of
CD8 expressing lymphocytes and a measurable effect
on better survival. Third, a better physiology as given
by a higher KPS could control the flexibility of the im-
mune system to raise an appropriate immune response.
Fig. 6 Schematic representation of effector cells guiding immune surveillance in GBM and counter regulatory CD39-positive cells. A number of
potential effector cells have been studied for their differential expression in GBM patients at the time of diagnosis. Based on regression analysis of
survival data based on the Cox proportional hazards model and model-based recursive partitioning, the beneficial effects of high numbers of
CD8-positive lymphocytes and the negative effect by CD39-positive lymphocytes has been demonstrated. Anti-tumor reactive CD8 cells may
migrate between the brain and the peripheral tissues. They are likely to be counter regulated by regulatory lymphocytes expressing CD39. CD39
cells may also migrate between tissues or may be induced by immune suppressive biomarkers which can be cytokines but also extracellular
vesicles. Tumor tissue is a likely source of such biomarkers.
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The immune alterations leading to tumor manifestation
are possibly related to remodeling of tolerogenic lym-
phocytes, a process which may be promoted in the eld-
erly [15, 30, 41]. We found a better survival in patients
with high relative amounts of CD95 lymphocytes
(Fig. 5d). Along these lines, Todo-Bom and colleagues
[41] detected more CD95 expression in elderly donors.
Activated NK cells may express CD95 and provide dir-
ect immune control by recognizing malignant cells with
low or negative expression of MHC antigens [42].
Moreover, glioblastoma cells express the CD95 ligand
[43] and may be susceptible to CD95 ligand-initiated
cell killing and therapy [44]. Moreover, CD95-positive
cytotoxic cells may trigger several pathways of caspase
activation in glioblastoma cell lines [45]. Although the
migration of activated lymphocytes between the periph-
eral blood and the brain has not been proven, the over-
all changes of immune phenotypes in GBM patients
strongly suggest ongoing crosstalk between the tumor
environment and the peripheral immune system (Fig. 6).
Based on univariable regression analysis followed by mul-
tivariable Cox proportional hazards model and recursive
partitioning, the absolute numbers of CD8-positive lym-
phocytes appear to be relevant for improved survival
(Additional file 1: Figure S2). Moreover, the relative
amounts of CD39-positive lymphocytes appear to be a
negative predictor. The correlation of CD39 (relative
amounts) and CD8 (absolute cell numbers) is significant
(p = 0.0033; r = −0.4332, (Additional file 7: Figure S5). A
model implementing these variables for survival with
functional aspects of immune cells has been provided in
Fig. 6. Accordingly, increased amounts of CD8 lympho-
cytes may eventually invade the tumor tissue and control
tumor cell proliferation. Effector cells are likely to be
counter regulated by regulatory T cells expressing CD39.
In addition to migrating immune cells between the brain
and the peripheral immune system, extracellular vesicles
released from tumor cells appear to play a major role to
potently activate tolerogenic T cells [46, 47], such vesicles
may be termed “immune suppressive biomarkers” as well.
Further studies and follow-up may substantiate the
current working hypothesis. After all, immunogenicity re-
mains to be the most important factor to control malignan-
cies. This hypothesis is currently supported by a likely
successful approach to immunize IDH-1 mutation-positive
tumor patients with IDH-1-derived peptides [14] and im-
proved survival of IDH-1-mutated patients [48].
Conclusions
Immune phenotypes in individual patients with GBM in-
dicate sensitization as well as anergy against glioblast-
oma tumor tissue. These observations may be exploited
to individualized immune-based therapeutic interventions
to eventually improve survival. Parameters can be also
used for clinical studies. Most important predictors are
mutated genes such as IDH-1, a patient's KPS, the ATP
nucleotidase CD39, and CD8 positive cytotoxic cells.
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